José A. Maldonado‐Cocco
About
José A. Maldonado‐Cocco is a scholar working on Rheumatology, Hematology and Immunology.
According to data from OpenAlex, José A. Maldonado‐Cocco has authored 35 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Rheumatology, 14 papers in Hematology and 10 papers in Immunology. Recurrent topics in José A. Maldonado‐Cocco's work include Rheumatoid Arthritis Research and Therapies (16 papers), Spondyloarthritis Studies and Treatments (13 papers) and Autoimmune and Inflammatory Disorders Research (13 papers). José A. Maldonado‐Cocco is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (16 papers), Spondyloarthritis Studies and Treatments (13 papers) and Autoimmune and Inflammatory Disorders Research (13 papers). José A. Maldonado‐Cocco collaborates with scholars based in Argentina, United States and Netherlands. José A. Maldonado‐Cocco's co-authors include María E. Suarez‐Almazor, David N. Glass, John Baum, Ross E. Petty, T. R. E. Southwood, Prudence Manners, Javier Orozco-Alcalá, Xiao-hu He, Anne‐Marie Prieur and José Goldenberg and has published in prestigious journals such as Annals of the Rheumatic Diseases, Medicine and Lara D. Veeken.
In The Last Decade
José A. Maldonado‐Cocco
34 papers receiving 4.9k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| José A. Maldonado‐Cocco Argentina | 17 | 3.5k | 2.0k | 1.3k | 990 | 951 | 35 | 5.0k | ||
| Ivan Foeldvari Germany | 34 | 1.6k 0.4× | 952 0.5× | 676 0.5× | 600 0.6× | 608 0.6× | 178 | 3.6k | ||
| Earl J. Brewer United States | 23 | 1.6k 0.4× | 872 0.4× | 656 0.5× | 319 0.3× | 397 0.4× | 45 | 2.4k | ||
| Sebastiaan J. Vastert Netherlands | 31 | 1.7k 0.5× | 645 0.3× | 700 0.5× | 889 0.9× | 1.3k 1.4× | 124 | 3.4k | ||
| Sadao Kashiwazaki Japan | 26 | 1.4k 0.4× | 1.2k 0.6× | 201 0.2× | 939 0.9× | 1.3k 1.4× | 126 | 3.9k | ||
| Barbara M. Ansell United Kingdom | 34 | 1.0k 0.3× | 1.5k 0.8× | 286 0.2× | 457 0.5× | 357 0.4× | 143 | 3.4k | ||
| Antonella Buoncompagni Italy | 27 | 1.4k 0.4× | 758 0.4× | 504 0.4× | 916 0.9× | 688 0.7× | 87 | 2.4k | ||
| Yelda Bilginer Türkiye | 28 | 693 0.2× | 648 0.3× | 195 0.2× | 1.5k 1.5× | 1.1k 1.1× | 198 | 3.1k | ||
| J.C. Piette France | 35 | 1.1k 0.3× | 2.2k 1.1× | 73 0.1× | 284 0.3× | 921 1.0× | 145 | 4.4k | ||
| Michael Frosch Germany | 28 | 842 0.2× | 487 0.2× | 254 0.2× | 1.4k 1.4× | 1.2k 1.2× | 65 | 2.9k | ||
| Kath Watson United Kingdom | 37 | 1.4k 0.4× | 3.6k 1.9× | 90 0.1× | 223 0.2× | 1.6k 1.7× | 79 | 5.8k |
Countries citing papers authored by José A. Maldonado‐Cocco
Since
Specialization
Citations
This map shows the geographic impact of José A. Maldonado‐Cocco's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by José A. Maldonado‐Cocco with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites José A. Maldonado‐Cocco more than expected).
Fields of papers citing papers by José A. Maldonado‐Cocco
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by José A. Maldonado‐Cocco. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by José A. Maldonado‐Cocco. The network helps show where José A. Maldonado‐Cocco may publish in the future.
Co-authorship network of co-authors of José A. Maldonado‐Cocco
This figure shows the co-authorship network connecting the top 25 collaborators of José A. Maldonado‐Cocco. A scholar is included among the top collaborators of José A. Maldonado‐Cocco based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with José A. Maldonado‐Cocco. José A. Maldonado‐Cocco is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Moltó, Anna, José A. Maldonado‐Cocco, Maxime Dougados, et al.. (2025). Trends to shorter diagnostic delay in spondyloarthritis patients during the last decades and association with clinical presentation: data from ASAS-COMOSPA study. RMD Open. 11(1). e004756–e004756.
2.
López‐Medina, Clementina, José A. Maldonado‐Cocco, Anna Moltó, et al.. (2024). Prevalence and incidence of uveitis in patients with spondyloarthritis: the impact of the biologics era. Data from the international ASAS-COMOSPA study. Lara D. Veeken. 64(5). 2618–2624.
3.
D’Agostino, Maria Antonietta, Georg Schett, Ladislav Šenolt, et al.. (2021). Response to secukinumab on synovitis using Power Doppler ultrasound in psoriatic arthritis: 12-week results from a phase III study, ULTIMATE. Lara D. Veeken. 61(5). 1867–1876.
4.
Reveille, John D., Proton Rahman, Talia M. Muram, et al.. (2021). P194 Response to ixekizumab by C-reactive protein level in patients with aadiographic axial spondyloarthritis: results from the COAST-V (biological-naïve) and COAST-W (TNF-α inhibitor-experienced) trials at 52 weeks. Lara D. Veeken. 60(Supplement_1).
5.
Genovese, Mark C., Désirée van der Heijde, Yong Lin, et al.. (2019). Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment. RMD Open. 5(2). e000887–e000887.
6.
Fleischmann, Roy, Yong Lin, Gregory St John, et al.. (2019). SAT0125 LONG-TERM SAFETY WITH SARILUMAB PLUS CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS AND SARILUMAB MONOTHERAPY IN RHEUMATOID ARTHRITIS: AN INTEGRATED ANALYSIS WITH 9,000 PATIENT-YEARS OF FOLLOW-UP. Annals of the Rheumatic Diseases. 78. 1130–1131.
7.
Curtis, Jeffrey R., Yong Lin, Karthinathan Thangavelu, et al.. (2019). FRI0081 WITHDRAWAL OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN THE SARILUMAB OPEN-LABEL EXTEND STUDY: EFFICACY AND SAFETY ANALYSIS. Annals of the Rheumatic Diseases. 78. 702–703.
8.
Fleischmann, Roy, Mark C. Genovese, Yong Lin, et al.. (2019). Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years’ follow-up. Lara D. Veeken. 59(2). 292–302.
9.
Fleischmann, R., Yong Lin, Gregory St John, et al.. (2019). 081 Long-term safety with sarilumab plus conventional synthetic disease-modifying antirheumatic drugs and sarilumab monotherapy in rheumatoid arthritis: an integrated analysis with 9,000 patient-years of follow-up. Lara D. Veeken. 58(Supplement_3).
10.
Bautista‐Molano, Wilson, Robert Landewé, R Burgos-Vargas, et al.. (2017). Prevalence of Comorbidities and Risk Factors for Comorbidities in Patients with Spondyloarthritis in Latin America: A Comparative Study with the General Population and Data from the ASAS-COMOSPA Study. The Journal of Rheumatology. 45(2). 206–212.
11.
Maldonado‐Cocco, José A., Gustavo Citera, Percival D. Sampaio‐Barros, et al.. (2016). Gender differences among patients with primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease in an iberoamerican spondyloarthritis cohort. Medicine. 95(51). e5652–e5652.
12.
Maldonado‐Cocco, José A., et al.. (2016). Secukinumab: a promising therapeutic option in spondyloarthritis. Clinical Rheumatology. 35(9). 2151–2161.
13.
Maldonado‐Cocco, José A., et al.. (2015). Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clinical Rheumatology. 35(2). 291–296.
14.
Maldonado‐Cocco, José A., et al.. (2011). Epidemiology of Spondyloarthritis in Argentina. The American Journal of the Medical Sciences. 341(4). 289–292.
15.
Bruyn, George A. W., Guillermo Tate, Francisco Caeiro, et al.. (2007). Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. Annals of the Rheumatic Diseases. 67(8). 1090–1095.
16.
Fleischmann, Roy, et al.. (2005). Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib. Clinical Rheumatology. 25(1). 42–53.
17.
Manners, Prudence, et al.. (2004). International League of Associations for Rheumatology classification of juvenile arthritis: second revision. UCL Discovery (University College London).
18.
Maldonado‐Cocco, José A., et al.. (2001). FRI0030 Treatment with etoricoxib (mk-0663), a cox-2 selective inhibitor, resulted in maintenance of clinical improvement in rheumatoid arthritis. Annals of the Rheumatic Diseases. 60. A457–A457.
19.
Hawkey, Christopher J., Loren Laine, Thomas Simon, et al.. (2000). Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. Arthritis & Rheumatism. 43(2). 370–370.
20.
Messina, Osvaldo Daniel, et al.. (1997). Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: A preliminary report. Clinical Rheumatology. 16(4). 346–352.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Ivan Foeldvari Breakdown of academic impact, for papers by Earl J. Brewer Breakdown of academic impact, for papers by Sebastiaan J. Vastert Breakdown of academic impact, for papers by Sadao Kashiwazaki Breakdown of academic impact, for papers by Barbara M. Ansell Breakdown of academic impact, for papers by Antonella Buoncompagni Breakdown of academic impact, for papers by Yelda Bilginer Breakdown of academic impact, for papers by J.C. Piette Breakdown of academic impact, for papers by Michael Frosch Breakdown of academic impact, for papers by Kath Watson